Cargando…
Determining the Factors Predicting the Response to Anti-HER2 Therapy in HER2-Positive Breast Cancer Patients
PURPOSE: We aimed to identify the differently expressed genes or related pathways associated with good responses to anti-HER2 therapy and to suggest a model for predicting drug response in neoadjuvant systemic therapy with trastuzumab in HER2-positive breast cancer patients. METHODS: This study was...
Autores principales: | You, Ji Young, Park, Kyoung Hwa, Lee, Eun Sook, Kwon, Youngmee, Kim, Kyoung Tae, Nam, Seungyoon, Kim, Dong Hee, Bae, Jeoung Won |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9950611/ https://www.ncbi.nlm.nih.gov/pubmed/36814068 http://dx.doi.org/10.1177/10732748221141672 |
Ejemplares similares
-
HER2 as a potential biomarker of lymph node metastasis in undifferentiated early gastric cancer
por: Han, Sanghoon, et al.
Publicado: (2020) -
Correlation of HER2, p95HER2 and HER3 Expression and Treatment Outcome of Lapatinib plus Capecitabine in her2-Positive Metastatic Breast Cancer
por: Han, Sae-Won, et al.
Publicado: (2012) -
Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer
por: Stanowicka-Grada, Malwina, et al.
Publicado: (2023) -
An Elaborate New Linker System Significantly Enhances the Efficacy of an HER2‐Antibody‐Drug Conjugate against Refractory HER2‐Positive Cancers
por: Shin, Seol Hwa, et al.
Publicado: (2021) -
Clinicopathologic characteristics of HER2-positive pure mucinous carcinoma of the breast
por: Jang, Yunjeong, et al.
Publicado: (2020)